Aaron Dane, MSc

Director
Danestat Consulting Limited, United Kingdom

Disclosure(s): Amplyx: Advisor/Consultant; AN2 therapeutics: Advisor/Consultant; Artizan: Advisor/Consultant; Cidara: Advisor/Consultant; ContraFect: Advisor/Consultant; Correvio: Advisor/Consultant; Davolterra: Advisor/Consultant; Destiny Pharma: Advisor/Consultant; Entasis: Advisor/Consultant; F2G Limited: Advisor/Consultant; GSK: Advisor/Consultant; Humanigen: Advisor/Consultant; Kymab: Advisor/Consultant; Modis: Advisor/Consultant; Orca: Advisor/Consultant; Pfizer: Advisor/Consultant; Phico: Advisor/Consultant; Pled Pharma: Advisor/Consultant; Rare Thyroid: Advisor/Consultant; Roche: Advisor/Consultant; Scynexis: Advisor/Consultant; Sinovent: Advisor/Consultant; Spero Therapeutics: Advisor/Consultant; Transcrip: Advisor/Consultant; Venatorx: Advisor/Consultant

Poster(s):

• 222 - Clinical and microbiological outcomes for Enterobacterales uropathogens in the Phase 3 ADAPT-PO Study of oral tebipenem pivoxil hydrobromide
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET